Arrayjet’s ArrayPlex platform selected by Immunome for use in its discovery of targeted cancer therapies

FHS
March 18, 2024
11:08 am

Immunome signs deal to use Arrayjet platform in its in-house screening operations.

Clinical trial shows CRISPR gene editing has exciting potential to treat a rare form of blindness

A recent study published in The New England Journal of Medicine investigated the potential use of gene editing to correct a congenital retinal degeneration called

May 8, 2024

Virtual Second Opinions on the Rise: Cardiology, Cancer, and Neurology Lead the Way

What You Should Know: – A new study by The Clinic by Cleveland Clinic has shed light on the increasing demand for virtual second opinions

September 17, 2024

As Amgen pursues GIP antagonism, a Novo Holdings-backed biotech does the same, boosting its Series A

Amgen’s obesity data are helping more than its own stock and internal R&D efforts. The biotech, which teased Phase 2 data in … Sign up

August 1, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.